Protective effects of trimetazidine on testicular ischemia-reperfusion injury in rats.
BACKGROUND
We tried to prove the effectiveness of trimetazidine (TMZ) on testicular torsion-detorsion injury.


METHODS
15 male rats were equally divided into three groups: group 1 was the sham-operated control group; group 2 had 2 h of unilateral testicular ischemia followed by 3 days of reperfusion, and group 3 had 2 h of unilateral testicular ischemia followed by 3 days of oral TMZ treatment (5 mg/kg, bid) during reperfusion. In the removed testicles, tissue reduced glutathione (GSH), glutathione reductase (GR), glutathione peroxidase (GPx), malondialdehyde (MDA) levels and pathological modified Johnson scores (MJS) were evaluated. Mann-Whitney U test was used for statistical evaluations.


RESULTS
In group 2, on the ipsilateral side, GSH were significantly lower and MDA were higher than in groups 1 and 3, though GSH and MDA were not statistically different between groups 1 and 3. On the other hand, GPx in the control testicles of group 3 was significantly lower compared to those in the counterparts of both groups 1 and 2. Among three groups, GR determined in both testicles were not statistically different. On the ipsilateral side, MJS in group 3 were lower than in the sham group, but significantly higher than in group 2.


CONCLUSIONS
According to this study, TMZ has an antioxidant effect on testicular torsion-detorsion injury, though the protective effect of TMZ seems to decrease in control testicles. Consequently it has been considered that TMZ can be only used in torsion patients with a healthy contralateral testicle after further studies have been conducted.
Unal
Dogan
D
Department of Urology, School of Medicine, Fatih University, Ankara, Turkey. dogunal@yahoo.com
Karatas
Omer F
OF
Savas
Murat
M
Yeni
Ercan
E
Keser
Bulent S
BS
Verit
Ayhan
A
Erel
Ozcan
O
Bitiren
Muharrem
M
D000818:Animals; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy*; D013737:Testis / Q000187:drug effects* / Q000473:pathology; D016896:Treatment Outcome; D014292:Trimetazidine / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D014292:Trimetazidine